# Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)

> **NCT00518687** · PHASE2,PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 8031 (actual)

## Conditions studied

- Staphylococcus Aureus
- Bacteremia
- Mediastinitis

## Interventions

- **BIOLOGICAL:** V710
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00518687
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 8031 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518687, "Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00518687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*